The Yin and Yang of Toll-like receptors in cancer

被引:247
作者
Pradere, J-P [1 ]
Dapito, D. H. [1 ,2 ]
Schwabe, R. F. [1 ,2 ]
机构
[1] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[2] Columbia Univ, Inst Human Nutr, New York, NY 10032 USA
关键词
MyD88; interleukin; 6; tumor necrosis factor; NF-kappa B; Coley's toxin; imiquimod; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DENDRITIC CELLS; CPG DNA; COMPENSATORY PROLIFERATION; PANCREATIC CARCINOGENESIS; HEPATOCELLULAR-CARCINOMA; LIVER-REGENERATION; GENE POLYMORPHISMS; TOPICAL IMIQUIMOD;
D O I
10.1038/onc.2013.302
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen-associated molecular patterns (PAMPs) but have also been implicated in the recognition of damage-associated molecular patterns (DAMPs). As such, TLRs regulate a wide range of biological responses including inflammatory and immune responses during carcinogenesis. The high expression of TLRs by antigen-presenting cells, including dendritic cells, and their ability to induce antitumor mediators such as type I interferon has led to efforts to utilize TLR agonists in tumor therapy in order to convert the often tolerant immune response toward antitumor responses. However, TLRs are also increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor survival signals. Here, we will review in detail the dichotomous role of TLRs in tumor biology, focusing on relevant TLR-dependent pro-and antitumor pathways, and discuss clinical applications of TLR-targeted therapies for tumor prevention and treatment.
引用
收藏
页码:3485 / 3495
页数:11
相关论文
共 187 条
[41]   WOUNDING AND ITS ROLE IN RSV-MEDIATED TUMOR-FORMATION [J].
DOLBERG, DS ;
HOLLINGSWORTH, R ;
HERTLE, M ;
BISSELL, MJ .
SCIENCE, 1985, 230 (4726) :676-678
[42]   Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells [J].
Drobits, Barbara ;
Holcmann, Martin ;
Amberg, Nicole ;
Swiecki, Melissa ;
Grundtner, Roland ;
Hammer, Martina ;
Colonna, Marco ;
Sibilia, Maria .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (02) :575-585
[43]   Human lung cancer cells express functionally active Toll-like receptor 9 [J].
Droemann, D ;
Albrecht, D ;
Gerdes, J ;
Ulmer, AJ ;
Branscheid, D ;
Vollmer, E ;
Dalhoff, K ;
Zabel, P ;
Goldmann, T .
RESPIRATORY RESEARCH, 2005, 6 (01)
[44]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998
[45]   Current insights into the regulation of programmed cell death by NF-κB [J].
Dutta, J. ;
Fan, Y. ;
Gupta, N. ;
Fan, G. ;
Gelinas, C. .
ONCOGENE, 2006, 25 (51) :6800-6816
[46]  
DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
[47]   Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation [J].
Ebihara, Takashi ;
Azuma, Masahiro ;
Oshiumi, Hiroyuki ;
Kasamatsu, Jun ;
Iwabuchi, Kazuya ;
Matsumoto, Kenji ;
Saito, Hirohisa ;
Taniguchi, Tadatsugu ;
Matsumoto, Misako ;
Seya, Tsukasa .
JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (12) :2675-2687
[48]   MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response [J].
Fabbri, Muller ;
Paone, Alessio ;
Calore, Federica ;
Galli, Roberta ;
Gaudio, Eugenio ;
Santhanam, Ramasamy ;
Lovat, Francesca ;
Fadda, Paolo ;
Mao, Charlene ;
Nuovo, Gerard J. ;
Zanesi, Nicola ;
Crawford, Melissa ;
Ozer, Gulcin H. ;
Wernicke, Dorothee ;
Alder, Hansjuerg ;
Caligiuri, Michael A. ;
Nana-Sinkam, Patrick ;
Perrotti, Danilo ;
Croce, Carlo M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (31) :E2110-E2116
[49]   Serum IgG autoantibodies directed against the a chain of Fc epsilon RI: A selective marker and pathogenetic factor for a distinct subset of chronic UrtiCaria patients? [J].
Fiebiger, E ;
Maurer, D ;
Holub, H ;
Reininger, B ;
Hartmann, G ;
Woisetschlager, M ;
Kinet, JP ;
Stingl, G .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2606-2612
[50]   A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease [J].
Fort, MM ;
Mozaffarian, A ;
Stöver, AG ;
Correia, JD ;
Johnson, DA ;
Crane, RT ;
Ulevitch, RJ ;
Persing, DH ;
Bielefeldt-Ohmann, H ;
Probst, P ;
Jeffery, E ;
Fling, SP ;
Hershberg, RM .
JOURNAL OF IMMUNOLOGY, 2005, 174 (10) :6416-6423